Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term - Scorecard - MDSpire
Advertisement
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
Clinical Scorecard: Intensive First-Line Chemo-Immunotherapy with Autologous Transplantation in 199 Patients with Mantle Cell Lymphoma: Long-Term Survival Benefits and Potential for Cure
At a Glance
Category
Detail
Condition
Mantle Cell Lymphoma (MCL), a rare and aggressive lymphoma
Key Mechanisms
Intensive first-line chemo-immunotherapy with rituximab and cytarabine-based high-dose sequential chemotherapy (R-HDS) combined with autologous stem cell transplantation (ASCT)
Target Population
Adult patients with CD20-positive MCL, median age 58 years, mostly advanced stage (Ann-Arbor III-IV), including typical and blastoid histology variants
Care Setting
Specialized cancer centers with capability for high-dose chemotherapy and autologous stem cell transplantation
Key Highlights
7-year overall survival (OS) of 67% and progression-free survival (PFS) of 53.2% after intensive R-HDS and ASCT treatment
85% of patients achieved complete or unconfirmed complete remission post-treatment, with 83% of long-term remissions lasting over 5 years
Prognostic factors such as MIPI score, age, LDH levels, and blastoid histology significantly influence long-term outcomes despite intensive therapy
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis with biopsy and CD20 positivity
Histological review according to 2017 WHO Classification to identify typical vs. blastoid variants
Assess MIPI score and Ki-67 proliferation index for prognostic stratification
Management
Administer intensive first-line chemo-immunotherapy using R-HDS protocol including rituximab and cytarabine
Perform peripheral blood stem cell harvest after high-dose cyclophosphamide and cytarabine
Conduct autologous stem cell transplantation (ASCT), with a second ASCT when feasible
Use involved field radiotherapy for bulky or residual disease post-ASCT
No maintenance rituximab recommended following R-HDS
Monitoring & Follow-up
Regular follow-up to assess remission status and detect relapse
Monitor for treatment-related toxicities and early deaths
Evaluate long-term survival and progression-free survival outcomes
Risks
Early treatment-related mortality (~2%)
Disease progression or toxic events precluding ASCT in some patients
Worse outcomes associated with high MIPI score, older age, elevated LDH, blastoid histology, and bulky disease
Patient & Prescribing Data
199 adult MCL patients treated in Italy from 1992 to 2017 with R-HDS and ASCT
High complete remission rates and long-term survival benefits observed; no significant survival difference between one vs. two ASCT procedures; blastoid histology associated with poorer prognosis
Clinical Best Practices
Use validated prognostic indices (MIPI) to stratify patients and guide treatment expectations
Implement intensive chemo-immunotherapy combined with ASCT as first-line treatment in eligible patients
Consider involved field radiotherapy for residual disease after ASCT
Avoid maintenance rituximab post R-HDS as per study protocol
Monitor closely for treatment-related toxicities and manage promptly
by Sergio Cortelazzo, Michael Mian, Andrea Evangelista, Liliana Devizzi, Paolo Corradini, Michele Magni, Marco Ladetto, Simone Ferrero, Andrea Rossi, Anna Maria Barbui, Caterina Patti, Alessandro Costa, Umberto Vitolo, Annalisa Chiappella, Fabio Benedetti, Andrés J. M. Ferreri, Paolo Nicoli, Luigi Rigacci, Claudia Castellino, Alessandro M. Gianni, Alessandro Rambaldi, Corrado Tarella
